GB0423173D0 - Treatment of diabetes - Google Patents

Treatment of diabetes

Info

Publication number
GB0423173D0
GB0423173D0 GBGB0423173.4A GB0423173A GB0423173D0 GB 0423173 D0 GB0423173 D0 GB 0423173D0 GB 0423173 A GB0423173 A GB 0423173A GB 0423173 D0 GB0423173 D0 GB 0423173D0
Authority
GB
United Kingdom
Prior art keywords
diabetes
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0423173.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Newcastle, The
Newcastle University of Upon Tyne
Original Assignee
University of Newcastle, The
Newcastle University of Upon Tyne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Newcastle, The, Newcastle University of Upon Tyne filed Critical University of Newcastle, The
Priority to GBGB0423173.4A priority Critical patent/GB0423173D0/en
Publication of GB0423173D0 publication Critical patent/GB0423173D0/en
Priority to PCT/GB2005/003974 priority patent/WO2006043036A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0423173.4A 2004-10-19 2004-10-19 Treatment of diabetes Ceased GB0423173D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0423173.4A GB0423173D0 (en) 2004-10-19 2004-10-19 Treatment of diabetes
PCT/GB2005/003974 WO2006043036A2 (en) 2004-10-19 2005-10-17 Treatment of diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0423173.4A GB0423173D0 (en) 2004-10-19 2004-10-19 Treatment of diabetes

Publications (1)

Publication Number Publication Date
GB0423173D0 true GB0423173D0 (en) 2004-11-24

Family

ID=33484794

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0423173.4A Ceased GB0423173D0 (en) 2004-10-19 2004-10-19 Treatment of diabetes

Country Status (2)

Country Link
GB (1) GB0423173D0 (en)
WO (1) WO2006043036A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2388317B1 (en) * 2009-01-07 2017-08-30 Hangzhou Yiyuan Biotechnology Co. Ltd. A gene encoding a human glucokinase mutant, and uses thereof in the treatment or prevention of disease
WO2013117776A1 (en) * 2012-02-08 2013-08-15 Fundación Pública Andaluza Progreso Y Salud Glucokinase enzymes with increased activity and use thereof in the treatment and/or prevention of diabetes mellitus
CN113244406B (en) * 2021-05-10 2022-12-16 清华大学 Use of agents for the manufacture of a medicament

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166592A1 (en) * 1999-07-19 2003-09-04 Monia Brett P. Antisense modulation of liver glycogen phosphorylase expression

Also Published As

Publication number Publication date
WO2006043036A3 (en) 2006-07-06
WO2006043036A2 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
EP1755584A4 (en) Treatment of myopia
IL218909A0 (en) Treatment of diabetes
EP1968591A4 (en) Treatment of synucleinopathies
EP1750698A4 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
GB2430002B (en) Well treatment
GB0625235D0 (en) Treatment of hydrocarbons
EP1718294A4 (en) Methods for treatment of complications of diabetes
EP1793813A4 (en) Treatment of adhd
GB0426196D0 (en) Methods of treatment
GB0426141D0 (en) Treatment
GB0424085D0 (en) Well treatment
EP1962882A4 (en) Compositions and methods for treatment of diabetes
GB0701549D0 (en) Skin treatment
GB0423173D0 (en) Treatment of diabetes
GB0425854D0 (en) Therapeutic treatment
GB0408521D0 (en) Treatment of sepsis
IL180709A0 (en) Treatment of tumours
GB0625234D0 (en) Treatment of Hydrocarbons
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
ZA200704046B (en) Treatment of burns
HU0400952D0 (en) Treatment of anus-cancer
GB0408752D0 (en) Therapeutic treatment
GB0407512D0 (en) Treatment of PCOS
GB0413470D0 (en) Treatment of pcos

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)